AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

French researchers are suggesting that measuring the density of positive programmed death ligand 1 cells in a biopsy might help predict response to immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC).

Results of the PIONeeR project, in which tumour tissue from 100 patients with advanced or metastatic disease was examined for 123 potential biomarkers were presented at the European Society for Medical Oncology (ESMO) virtual congress 2020.

All patients (64% male) had tumour tissue archived at baseline and were treated according to guidelines with nivolimumab, pembrolizumab or atezolizumab either as second-line monotherapy or first-line with chemotherapy.